Skip to main content
SpringerPlus
Fig. 2 | SpringerPlus

Fig. 2

From: A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

Fig. 2

Treatment differences and 97.5 % confidence intervals by subgroup. a Subgroup analysis of the Lambda/RBV versus alfa/RBV treatment difference and 97.5 % confidence intervals. b Subgroup analysis of the Lambda/RBV + DCV versus alfa/RBV treatment difference and 97.5 % confidence intervals. alfa peginterferon alfa-2a, BMI body mass index, DCV daclatasvir, GT genotype, Lambda peginterferon Lambda-1a, RBV ribavirin

Back to article page